AMSTERDAM, January 31 /PRNewswire/ -- Oncology focused
biopharmaceutical product development company Kiadis Pharma announced today
that it has successfully finalized its Rhitol(TM) Phase II clinical trial
with the last patient completing its six month treatment cycle. Rhitol(TM)
is evaluated as treatment for patients with extensive chronic Graft versus
Host Disease (GvHD) intolerant or resistant to standard immunosuppressive
treatment.
The current preliminary clinical results demonstrate an excellent
safety profile for Rhitol(TM) and evidence of efficacy in the alleviation
of the symptoms associated with chronic Graft versus Host Disease. After
this clinical study was closed for enrollment mid 2007 Kiadis Pharma
allowed new patients to be treated under a compassionate protocol. The
successful completion of the Phase II clinical trial of Rhitol(TM) paves
the way for a phase III study and Kiadis Pharma is planning to file for a
phase III multi center clinical trial in the USA and Canada within the next
few months.
Manja Bouman, CEO Kiadis Pharma comments: "We are very pleased with the
positive outcome of this study and the potential shown by Rhitol(TM). This
product would fulfill a significant unmet medical need since patients with
chronic GvHD resistant or intolerant to immunosuppressive drugs have no
other standard treatment option available to them and this disease can
subsequently develop into a life-threatening condition."
To read the complete press releases please go to http://www.kiadis.com
English release is provided by Kiadis Pharma. Equivalent translations
are from a third party.